ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0625

Brief Tailored Clinic Intervention (A-MATIC) Targets Nonadherence During SLE Visits: Two-year Sustainability and Outcomes

Shivani Garg1, Betty Chewning1, Shelby Gomez1 and Christie Bartels2, 1UW Madison, Madison, WI, 2University of Wisconsin School of Medicine and Public Health, Madison, WI

Meeting: ACR Convergence 2021

Keywords: adherence, improving adherence, Lupus, sustainable, tailored intervention

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Measures & Measurement of Healthcare Quality Poster (0623–0659)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Up to 83% of SLE patients are nonadherent to hydroxychloroquine (HCQ) which can result in up to 8-fold higher risk of early death. Yet, adherence is never assessed during routine SLE visits. Current adherence tools are time-consuming and offer no guidance to clinicians for adherence discussions. Our prior study reported feasibility of using an adapted seven-item Assessing Medication Adherence & Tailoring Intervention in Clinic (A-MATIC) process that identifies nonadherence and facilitates tailored adherence discussions in 2.6 mins. This study examined the impact and sustainability of using A-MATIC during SLE visits.

Methods: Our study included all patients seen at the UW SLE Clinic between 3/2019-5/2021. A-MATIC intervention is adapted from two standard adherence tools, Medication Adherence Self-Report Inventory (MASRI) and Brief Medication Questionnaire (BMQ), and includes 4 steps (Table 1): Step 1, assesses adherence using 0-140% MASRI visual analogue scale (VAS). The tool prompts patients reporting adherence < 80% to proceed to Step 2. Step 2, has 6-items BMQ-derived to identify key barriers. Step 3, contains adherence planning strategies that crosswalks from Step 2 barriers. Using these strategies, clinician can tailor an adherence plan based on patient choices in Step 4. Last, the clinician circles strategies used and time spent.

To assess impact, we examined the change in adherence across 3 follow-up (f/u) visits after patients participated in tailored patient-clinician discussions using A-MATIC compared to baseline adherence. We calculated the mean difference in adherence and examined the trend of adherence over time. To assess sustainability, we calculated the mean time spent and percentage of intervention completed at baseline, 1st, 2nd, 3rd f/u visits. Intervention completion was defined as patients and clinicians completing all steps.

Results: In study period there were 250 visits of 87 SLE patients with demographics shown in Table 2.
Impact – We found 36% (31/87) of the patients reported nonadherence at baseline. All patients reporting nonadherence participated in tailored adherence planning with their clinician. During the 1st f/u, 96% of these patients reported >80% HCQ adherence and resolution of underlying barriers; these patients reported HCQ adherence on their subsequent f/u. We found 93% lower odds of reported nonadherence after completing the A-MATIC intervention and participating in adherence discussions (OR 0.07, CI 0.01-0.24, p < 0.001). Significant improvement in adherence was noted over time (Mean diff. 27%, CI 16%-38%, p < 0.001) (Fig. 1A). Finally, over 2 years, 95% of patients reported >80% adherence compared to 64% at baseline.

Sustainability – Over 2 years, the mean time to complete the intervention was 2.6±1 mins, 1.1±0.2 mins, 1.1±0.2 mins, 1.05±0.2 mins. during baseline, 1st, 2nd, 3rd f/u; the intervention was completed during 99%, 95%, 81%, 81% of the baseline, 1st, 2nd, 3rd f/u visits. (Fig. 1B).

Conclusion: A-MATIC intervention is a sustainable and impactful way to assess and facilitate adherence discussions between a patient and clinician, and helps sustain adherence over time. Next study will examine A-MATIC’s role in targeting nonadherence in diverse SLE clinics.

Table 1. A-MATIC* Intervention Process.
*A-MATIC is adapted from 2 validated gold-standard adherence tools (MASRI & BMQ). MASRI Medication Adherence Self-Report Inventory; BMQ Brief Medication Questionnaire

Table 2. Patient Demographics

Figure 1. 1A. Graph showing impact of A-MATIC defined as proportion of adherence over two years; 1B. Graph showing sustainability of using A-MATIC during routine SLE visits over two years.


Disclosures: S. Garg, None; B. Chewning, None; S. Gomez, None; C. Bartels, Pfizer, Independent Grants for Learning and Change, 5.

To cite this abstract in AMA style:

Garg S, Chewning B, Gomez S, Bartels C. Brief Tailored Clinic Intervention (A-MATIC) Targets Nonadherence During SLE Visits: Two-year Sustainability and Outcomes [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/brief-tailored-clinic-intervention-a-matic-targets-nonadherence-during-sle-visits-two-year-sustainability-and-outcomes/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/brief-tailored-clinic-intervention-a-matic-targets-nonadherence-during-sle-visits-two-year-sustainability-and-outcomes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology